Condition: Melanoma · Sponsor: Loyola University
Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced melanoma.
This description comes directly from the study's public registry record.
Michael Nishimura, PhD · 708-327-3241 · mnishimura@lumc.edu
Ann Lau Clark, RN, MSN · 708-327-3221 · alausch@luc.edu
Always discuss trial participation with your own doctor first.
| Loyola University Medical Center | Maywood, Illinois, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02870244